Clinical trials: Antiphospholipid (aPL)-Positive
Antiphospholipid (aPL)-Positive
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
The primary purpose of this study was to evaluate the safety and tolerability of intravenous (IV) ALXN1007 in persistently antiphospholipid (aPL)-positive patients with at least 1 of the following non-criteria manifestations of…
- Trial name
- NCT02128269
- Testing
- Study Drug- ALXN1007
- Where
- 9 sites in United States, Brazil and 4 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
This 12 week study will observe patients with and without systemic lupus erythematosus who have persistent antiphospholipid antibodies in the blood who are starting a medicine called hydroxychloroquine.
- Conditions
- Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody, Systemic Lupus Erythematosus
- Trial name
- NCT01475149
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Hospital for Special Surgery, New York
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Antiphospholipid (aPL)-Positive, Thrombocytopaenia
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
The goal of this clinical trial is to evaluate the efficacy and safety of sirolimus in patients with anti-phospholipid antibody-associated thrombocytopenia.
- Trial name
- SMART (NCT06722586)
- Testing
- Sirolimus
- Where
- 10 sites in China
- Volunteers
- 84 people
- Sponsor
- Peking University First Hospital
Antiphospholipid Syndrome
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
- Trial name
- NCT01784523
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Hospital for Special Surgery, New York